Publicação
zAvatar-test—a functional precision model to personalize ovarian cancer treatments: Results from a co-clinical study
| datacite.subject.sdg | 03:Saúde de Qualidade | |
| datacite.subject.sdg | 09:Indústria, Inovação e Infraestruturas | |
| datacite.subject.sdg | 04:Educação de Qualidade | |
| dc.contributor.author | Estrada, Marta F. | |
| dc.contributor.author | Amorim, Filipa | |
| dc.contributor.author | Silva, Filipa Ferreira da | |
| dc.contributor.author | Almeida, Cátia Rebelo de | |
| dc.contributor.author | Fontes, Márcia | |
| dc.contributor.author | Coelho, Ricardo | |
| dc.contributor.author | Ferreira, Sónia | |
| dc.contributor.author | Canas-Marques, Rita | |
| dc.contributor.author | Castillo-Martin, Mireia | |
| dc.contributor.author | Casanova, João | |
| dc.contributor.author | Batarda, Maria de Lurdes | |
| dc.contributor.author | Yaniz-Galende, Elisa | |
| dc.contributor.author | LeFormal, Audrey | |
| dc.contributor.author | Marreiros, Ana | |
| dc.contributor.author | Jacob, Francis | |
| dc.contributor.author | Heinzelmann-Schwarz, Viola | |
| dc.contributor.author | Leary, Alexandra | |
| dc.contributor.author | Nabais, Henrique | |
| dc.contributor.author | Fior, Rita | |
| dc.date.accessioned | 2026-03-05T13:01:36Z | |
| dc.date.available | 2026-03-05T13:01:36Z | |
| dc.date.issued | 2026-01 | |
| dc.description.abstract | In ovarian cancer, 80% of patients relapse after first-line therapy. In recurrent cases, oncologists lack reliable tests to guide chemotherapy choices, creating an unmet clinical need. Here, we develop the ovarian cancer zebrafish Avatar-test, a functional in vivo model using patient tumor cells implanted in zebrafish embryos to predict treatment responses. We present the largest observational study (32 patients), where the zAvatar-test achieves 91% accuracy in predicting patient outcomes. Patients with a zAvatar-sensitive-test correlate with longer progression-free survival (17 vs. 6 months). Tumors in zAvatars are dynamic, with human-host cell interactions, and higher metastatic potential in poor-prognosis cases. Finally, as a proof of concept, we demonstrate that venetoclax has the potential to sensitize multidrug-resistant tumors. Altogether, this clinical study demonstrates that the zAvatar-test may help clinicians personalize treatments for ovarian cancer patients. We are now conducting a multicentric randomized clinical trial to evaluate the zAvatar-test as a companion tool in clinical oncology. | eng |
| dc.description.sponsorship | PTDC/BTM-SAL/3796/2021 | |
| dc.identifier.doi | 10.1016/j.xcrm.2025.102530 | |
| dc.identifier.issn | 2666-3791 | |
| dc.identifier.uri | http://hdl.handle.net/10400.1/28342 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.publisher | Elsevier | |
| dc.relation.ispartof | Cell Reports Medicine | |
| dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
| dc.title | zAvatar-test—a functional precision model to personalize ovarian cancer treatments: Results from a co-clinical study | eng |
| dc.type | journal article | |
| dspace.entity.type | Publication | |
| oaire.citation.issue | 1 | |
| oaire.citation.title | Cell Reports Medicine | |
| oaire.citation.volume | 7 | |
| oaire.version | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |
| person.familyName | Marreiros | |
| person.givenName | Ana | |
| person.identifier.ciencia-id | 9A12-9450-7051 | |
| person.identifier.orcid | 0000-0001-9410-4772 | |
| person.identifier.scopus-author-id | 57194785077 | |
| relation.isAuthorOfPublication | c0a8e5da-26ae-42a8-ab04-fa4df4356375 | |
| relation.isAuthorOfPublication.latestForDiscovery | c0a8e5da-26ae-42a8-ab04-fa4df4356375 |